TY - JOUR AU - Tarján, Dorottya AU - Szalai, Eszter AU - Lipp, Mónika Bernadett AU - Verbói, Máté AU - Kói, Tamás AU - Erőss, Bálint Mihály AU - Teutsch, Brigitta AU - Faluhelyi, Nándor AU - Hegyi, Péter AU - Mikó, Alexandra TI - Persistently High Procalcitonin and C-Reactive Protein Are Good Predictors of Infection in Acute Necrotizing Pancreatitis: A Systematic Review and Meta-Analysis JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 2 PG - 14 SN - 1661-6596 DO - 10.3390/ijms25021273 UR - https://m2.mtmt.hu/api/publication/34530314 ID - 34530314 N1 - * Megosztott szerzőség AB - Infected necrotizing pancreatitis (INP) is associated with an increased risk of organ failure and mortality. Its early recognition and timely initiation of antibiotic therapy can save patients’ lives. We systematically searched three databases on 27 October 2022. In the eligible studies, the presence of infection in necrotizing pancreatitis was confirmed via a reference test, which involved either the identification of gas within the necrotic collection through computed tomography imaging or the examination of collected samples, which yielded positive results in Gram staining or culture. Laboratory biomarkers compared between sterile necrotizing pancreatitis and INP were used as the index test, and our outcome measures included sensitivity, specificity, the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC). Within the first 72 hours (h) after admission, the AUC of C-reactive protein (CRP) was 0.69 (confidence interval (CI): 0.62–0.76), for procalcitonin (PCT), it was 0.69 (CI: 0.60–0.78), and for white blood cell count, it was 0.61 (CI: 0.47–0.75). After the first 72 h, the pooled AUC of CRP showed an elevated level of 0.88 (CI: 0.75–1.00), and for PCT, it was 0.86 (CI: 0.60–1.11). The predictive value of CRP and PCT for infection is poor within 72 h after hospital admission but seems good after the first 72 h. Based on these results, infection is likely in case of persistently high CRP and PCT, and antibiotic initiation may be recommended. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Rita AU - Ocskay, Klementina AU - Sipos, Zoltán AU - Szentesi, Andrea Ildikó AU - Vincze, Áron AU - Czakó, László AU - Izbéki, Ferenc AU - Shirinskaya, Natalia V AU - Poluektov, Vladimir L AU - Zolotov, Alexandr N AU - Zhu, Yin AU - Xia, Liang AU - He, Wenhua AU - Sutton, Robert AU - Szatmary, Peter AU - Mukherjee, Rajarshi AU - Burridge, Isobel Saffron AU - Wauchope, Emma AU - Francisco, Elsa AU - Aparicio, David AU - Pinto, Bruno AU - Gomes, António AU - Nunes, Vitor AU - Tantau, Vasile Marcel AU - Sagau, Emanuela Denisa AU - Tantau, Alina Ioana AU - Suceveanu, Andra Iulia AU - Tocia, Cristina AU - Dumitru, Andrei AU - Pando, Elizabeth AU - Alberti, Piero AU - Cirera, Arturo AU - Molero, Xavier AU - Lee, Hong Sik AU - Jung, Min Kyu AU - Kim, Eui Joo AU - Lee, Sanghyub AU - Rebollo, María Lourdes Ruiz AU - Nistal, Reyes Busta AU - Santervas, Sandra Izquierdo AU - Lesko, Dusan AU - Soltes, Marek AU - Radonak, Jozef AU - Zatorski, Hubert AU - Małecka-Panas, Ewa AU - Fabisiak, Adam AU - Yaroslav, M Susak AU - Mykhailo, V Maksymenko AU - Olekcandr, A Tkachenko AU - Barauskas, Giedrius AU - Simanaitis, Vytautas AU - Ignatavicius, Povilas AU - Jinga, Mariana AU - Balaban, Vasile-Daniel AU - Patoni, Cristina AU - Gong, Liang AU - Song, Kai AU - Li, Yunlong AU - Gonçalves, T Cúrdia AU - Freitas, Marta AU - Macedo, Vítor AU - Vornhuelz, Marlies AU - Klauss, Sarah AU - Beyer, Georg AU - Koksal, Aydin Seref AU - Tozlu, Mukaddes AU - Eminler, Ahmet Tarik AU - Monclús, Nuria Torres AU - Comas, Eva Pijoan AU - Oballe, Juan Armando Rodriguez AU - Nawacki, Łukasz AU - Głuszek, Stanisław AU - Rama-Fernández, Alberto AU - Galego, Marco AU - de la Iglesia, Daniel AU - Aykut, Umut Emre AU - Duman, Deniz Güney AU - Aslan, Rahmi AU - Gherbon, Adriana AU - Deng, Lihui AU - Huang, Wei AU - Xia, Qing AU - Poropat, Goran AU - Radovan, Anja AU - Vranić, Luka AU - Ricci, Claudio AU - Ingaldi, Carlo AU - Casadei, Riccardo AU - Negoi, Ionut AU - Ciubotaru, Cezar AU - Iordache, Florin Mihail AU - Constantinescu, Gabriel AU - Sandru, Vasile AU - Altintas, Engin AU - Balci, Hatice Rizaoglu AU - Constantino, Júlio AU - Aveiro, Débora AU - Pereira, Jorge AU - Gunay, Suleyman AU - Misirlioglu Sucan, Seda AU - Dronov, Oleksiy AU - Kovalska, Inna AU - Bush, Nikhil AU - Rana, Surinder Singh AU - Chooklin, Serge AU - Chuklin, Serhii AU - Saizu, Ionut Adrian AU - Gheorghe, Cristian AU - Göltl, Philipp AU - Hirth, Michael AU - Mateescu, Radu Bogdan AU - Papuc, Geanina AU - Minkov, Georgi Angelov AU - Enchev, Emil Tihomirov AU - Mastrangelo, Laura AU - Jovine, Elio AU - Chen, Weiwei AU - Zhu, Quping AU - Gąsiorowska, Anita AU - Fabisiak, Natalia AU - Bezmarevic, Mihailo AU - Litvin, Andrey AU - Mottes, Martina Cattani AU - Choi, Eun Kwang AU - Bánovčin, Peter AU - Nosáková, Lenka AU - Kovacheva-Slavova, Mila Dimitrova AU - Kchaou, Ali AU - Tlili, Ahmed AU - Marino, Marco V AU - Kusnierz, Katarzyna AU - Mickevicius, Artautas AU - Hollenbach, Marcus AU - Molcan, Pavol AU - Ioannidis, Orestis AU - Tokarev, Mark Valerievich AU - Ince, Ali Tüzün AU - Semenenko, Ivan Albertovich AU - Galeev, Shamil AU - Ramírez-Maldonado, Elena AU - Sallinen, Ville AU - Pencik, Petr AU - Bajor, Judit AU - Sarlós, Patrícia AU - Hágendorn, Roland AU - Gódi, Szilárd AU - Szabó, Imre AU - Czimmer, József AU - Pár, Gabriella AU - Illés, Anita AU - Faluhelyi, Nándor AU - Kanizsai, Péter László AU - Nagy, Tamás AU - Mikó, Alexandra AU - Németh, Balázs AU - Hamvas, József AU - Bod, Barnabás AU - Varga, Márta AU - Török, Imola AU - Novák, János AU - Patai, Árpád AU - Sümegi, János AU - Góg, Csaba AU - Papp, Mária AU - Erőss, Bálint Mihály AU - Váncsa, Szilárd AU - Teutsch, Brigitta AU - Márta, Katalin AU - Hegyi, Péter Jenő AU - Tornai, Tamás AU - Lázár, Balázs AU - Hussein, Tamás AU - Tarján, Dorottya AU - Lipp, Mónika Bernadett AU - Kovács, Beáta AU - Urbán, Orsolya AU - Fürst, Emese Rita AU - Tari, Edina AU - Kocsis, Ibolya AU - Maurovich-Horvat, Pál AU - Tihanyi, Balázs AU - Eperjesi, Orsolya AU - Kormos, Zita AU - Deák, Pál Ákos AU - Párniczky, Andrea AU - Hegyi, Péter TI - Discharge protocol in acute pancreatitis: an international survey and cohort analysis JF - SCIENTIFIC REPORTS J2 - SCI REP VL - 13 PY - 2023 IS - 1 PG - 10 SN - 2045-2322 DO - 10.1038/s41598-023-48480-z UR - https://m2.mtmt.hu/api/publication/34434496 ID - 34434496 AB - There are several overlapping clinical practice guidelines in acute pancreatitis (AP), however, none of them contains suggestions on patient discharge. The Hungarian Pancreatic Study Group (HPSG) has recently developed a laboratory data and symptom-based discharge protocol which needs to be validated. (1) A survey was conducted involving all members of the International Association of Pancreatology (IAP) to understand the characteristics of international discharge protocols. (2) We investigated the safety and effectiveness of the HPSG-discharge protocol. According to our international survey, 87.5% (49/56) of the centres had no discharge protocol. Patients discharged based on protocols have a significantly shorter median length of hospitalization (LOH) (7 (5;10) days vs. 8 (5;12) days) p < 0.001), and a lower rate of readmission due to recurrent AP episodes (p = 0.005). There was no difference in median discharge CRP level among the international cohorts (p = 0.586). HPSG-protocol resulted in the shortest LOH (6 (5;9) days) and highest median CRP (35.40 (13.78; 68.40) mg/l). Safety was confirmed by the low rate of readmittance (n = 35; 5%). Discharge protocol is necessary in AP. The discharge protocol used in this study is the first clinically proven protocol. Developing and testifying further protocols are needed to better standardize patients' care. LA - English DB - MTMT ER - TY - JOUR AU - Lipp, Mónika Bernadett AU - Tarján, Dorottya AU - Lee, Jimin AU - Zolcsák, Ádám AU - Szalai, Eszter AU - Teutsch, Brigitta AU - Faluhelyi, Nándor AU - Erőss, Bálint Mihály AU - Hegyi, Péter AU - Mikó, Alexandra TI - Fatty Pancreas Is a Risk Factor for Pancreatic Cancer: A Systematic Review and Meta-Analysis of 2956 Patients JF - CANCERS J2 - CANCERS VL - 15 PY - 2023 IS - 19 PG - 14 SN - 2072-6694 DO - 10.3390/cancers15194876 UR - https://m2.mtmt.hu/api/publication/34211988 ID - 34211988 N1 - * Megosztott szerzőség AB - Pancreatic cancer (PC) is one of the most lethal cancers worldwide. Recently, fatty pancreas (FP) has been studied thoroughly, and although its relationship to PC is not fully understood, FP is suspected to contribute to the development of PC. We aimed to assess the association between PC and FP by conducting a systematic review and meta-analysis. We systematically searched three databases, MEDLINE, Embase, and CENTRAL, on 21 October 2022. Case-control and cross-sectional studies reporting on patients where the intra-pancreatic fat deposition was determined by modern radiology or histology were included. As main outcome parameters, FP in patients with and without PC and PC in patients with and without FP were measured. Proportion and odds ratio (OR) with a 95% confidence interval (CI) were used for effect size measure. PC among patients with FP was 32% (OR 1.32; 95% CI 0.42-4.16). However, the probability of having FP among patients with PC was more than six times higher (OR 6.13; 95% CI 2.61-14.42) than in patients without PC, whereas the proportion of FP among patients with PC was 0.62 (95% CI 0.42-0.79). Patients identified with FP are at risk of developing PC. Proper screening and follow-up of patients with FP may be recommended. LA - English DB - MTMT ER - TY - JOUR AU - Váncsa, Szilárd AU - Sipos, Zoltán AU - Váradi, Alex AU - Nagy, Rita AU - Ocskay, Klementina AU - Juhász, Márk Félix AU - Márta, Katalin AU - Teutsch, Brigitta AU - Mikó, Alexandra AU - Hegyi, Péter Jenő AU - Vincze, Áron AU - Izbéki, Ferenc AU - Czakó, László AU - Papp, Mária AU - Hamvas, József AU - Varga, Márta AU - Török, Imola AU - Mickevicius, Artautas AU - Erőss, Bálint Mihály AU - Párniczky, Andrea AU - Szentesi, Andrea Ildikó AU - Pár, Gabriella AU - Hegyi, Péter ED - Imrei, Marcell / Collaborator ED - Földi, Mária / Collaborator ED - Miklós, Emőke / Collaborator ED - Gódi, Szilárd / Collaborator ED - Hágendorn, Roland / Collaborator ED - Sarlós, Patricia / Collaborator ED - Bajor, Judit / Collaborator ED - Szabó, Imre / Collaborator ED - Czimmer, József / Collaborator ED - Faluhelyi, Nándor / Collaborator ED - Farkas, Orsolya / Collaborator ED - Kanizsai, Péter / Collaborator ED - Nagy, Tamás / Collaborator ED - Németh, Balázs / Collaborator ED - Kui, Balázs / Collaborator ED - Illés, Dóra / Collaborator ED - Takács, Tamás / Collaborator ED - Gajdán, László / Collaborator ED - Vitális, Zsuzsanna / Collaborator ED - Bod, Barnabás / Collaborator ED - Novák, János / Collaborator ED - Macarie, Melania / Collaborator ED - Maurovich-Horvat, Pál / Collaborator ED - Doros, Attila / Collaborator ED - Deák, Pál Ákos / Collaborator ED - Varga, Csaba / Collaborator ED - Gaál, Szabolcs / Collaborator ED - Zubek, László / Collaborator ED - Gál, János / Collaborator ED - Patai, Árpád / Collaborator ED - Tornai, Tamás / Collaborator ED - Lázár, Balázs / Collaborator ED - Hussein, Tamás / Collaborator ED - Kovács, Beáta / Collaborator ED - Tarján, Dorottya / Collaborator ED - Lipp, Mónika Bernadett / Collaborator ED - Urbán, Orsolya / Collaborator ED - Emese, Fürst / Collaborator ED - Tari, Edina / Collaborator TI - Metabolic-associated fatty liver disease is associated with acute pancreatitis with more severe course : Post hoc analysis of a prospectively collected international registry JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - 4 SP - 371 EP - 382 PG - 12 SN - 2050-6406 DO - 10.1002/ueg2.12389 UR - https://m2.mtmt.hu/api/publication/33761635 ID - 33761635 N1 - Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary Centre for Translational Medicine, Semmelweis University, Budapest, Hungary Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary Institute of Bioanalysis, Medical School, University of Pécs, Pécs, Hungary Department of Metagenomics, University of Debrecen, Debrecen, Hungary Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary Heim Pál National Pediatric Institute, Budapest, Hungary Department of Medical Genetics, Medical School, University of Pécs, Pécs, Hungary Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary Szent György University Teaching Hospital of Fejér County, Székesfehérvár, Hungary Department of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary Department of Gastroenterology, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary Peterfy Hospital, Budapest, Hungary Department of Gastroenterology, BMKK Dr. Réthy Pál Hospital, Békéscsaba, Hungary County Emergency Clinical Hospital of Targu Mures - Gastroenterology and George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Targu Mures, Romania Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania Clinics of Abdominal Surgery, Nephrology and Gastroenterology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation University of Szeged, Szeged, Hungary Cited By :1 Export Date: 1 October 2023 Correspondence Address: Hegyi, P.Szigeti Street 12, Hungary; email: hegyi2009@gmail.com AB - Non-alcoholic fatty liver disease (NAFLD) is a proven risk factor for acute pancreatitis (AP). However, NAFLD has recently been redefined as metabolic-associated fatty liver disease (MAFLD). In this post hoc analysis, we quantified the effect of MAFLD on the outcomes of AP.We identified our patients from the multicentric, prospective International Acute Pancreatitis Registry of the Hungarian Pancreatic Study Group. Next, we compared AP patients with and without MAFLD and the individual components of MAFLD regarding in-hospital mortality and AP severity based on the revised Atlanta classification. Lastly, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression analysis.MAFLD had a high prevalence in AP, 39% (801/2053). MAFLD increased the odds of moderate-to-severe AP (OR = 1.43, CI: 1.09-1.89). However, the odds of in-hospital mortality (OR = 0.89, CI: 0.42-1.89) and severe AP (OR = 1.70, CI: 0.97-3.01) were not higher in the MAFLD group. Out of the three diagnostic criteria of MAFLD, the highest odds of severe AP was in the group based on metabolic risk abnormalities (OR = 2.68, CI: 1.39-5.09). In addition, the presence of one, two, and three diagnostic criteria dose-dependently increased the odds of moderate-to-severe AP (OR = 1.23, CI: 0.88-1.70, OR = 1.38, CI: 0.93-2.04, and OR = 3.04, CI: 1.63-5.70, respectively) and severe AP (OR = 1.13, CI: 0.54-2.27, OR = 2.08, CI: 0.97-4.35, and OR = 4.76, CI: 1.50-15.4, respectively). Furthermore, in patients with alcohol abuse and aged ≥60 years, the effect of MAFLD became insignificant.MAFLD is associated with AP severity, which varies based on the components of its diagnostic criteria. Furthermore, MAFLD shows a dose-dependent effect on the outcomes of AP. LA - English DB - MTMT ER - TY - JOUR AU - Kovács, Norbert AU - Pécsi, Dániel AU - Sipos, Zoltán AU - Borbásné Farkas, Kornélia AU - Földi, Mária AU - Hegyi, Péter AU - Bajor, Judit AU - Erőss, Bálint Mihály AU - Márta, Katalin AU - Mikó, Alexandra AU - Rakonczay, Zoltán AU - Sarlós, Patrícia AU - Ábrahám, Szabolcs AU - Vincze, Áron TI - Suprapapillary Biliary Stents Have Longer Patency Times than Transpapillary Stents-A Systematic Review and Meta-Analysis. JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 12 PY - 2023 IS - 3 PG - 16 SN - 2077-0383 DO - 10.3390/jcm12030898 UR - https://m2.mtmt.hu/api/publication/33636629 ID - 33636629 N1 - * Megosztott szerzőség AB - Endoscopic biliary stent placement is a minimally invasive intervention for patients with biliary strictures. Stent patency and function time are crucial factors. Suprapapillary versus transpapillary stent positioning may contribute to stent function time, so a meta-analysis was performed in this comparison.A comprehensive literature search was conducted in the CENTRAL, Embase, and MEDLINE databases to find data on suprapapillary stent placement compared to the transpapillary method via endoscopic retrograde cholangiopancreatography in cases of biliary stenosis of any etiology and any stent type until December 2020. We carried out a meta-analysis focusing on the following outcomes: stent patency, stent migration, rate of cholangitis and pancreatitis, and other reported complications.Three prospective and ten retrospective studies involving 1028 patients were included. Suprapapillary stent placement appeared to be superior to transpapillary stent positioning in patency (weighted mean difference = 50.23 days, 95% CI: 8.56, 91.98; p = 0.0.018). In a subgroup analysis of malignant indications, suprapapillary positioning showed a lower rate of cholangitis (OR: 0.34, 95% CI: 0.13, 0.93; p = 0.036). Another subgroup analysis investigating metal stents in a suprapapillary position resulted in a lower rate of pancreatitis (OR: 0.16, 95% CI: 0.03, 0.95; p = 0.043) compared to transpapillary stent placement. There was no difference in stent migration rates between the two groups (OR: 0.67, 95% CI: 0.17, 2.72; p = 0.577).Based on our results, suprapapillary biliary stenting has longer stent patency. Moreover, the stent migration rate did not differ between the suprapapillary and transpapillary groups. LA - English DB - MTMT ER - TY - JOUR AU - Nagy, Rita AU - Ocskay, Klementina AU - Váradi, Alex AU - Papp, Mária AU - Vitális, Zsuzsanna AU - Izbéki, Ferenc AU - Boros, Eszter AU - Gajdán, László AU - Szentesi, Andrea Ildikó AU - Erőss, Bálint Mihály AU - Hegyi, Péter Jenő AU - Vincze, Áron AU - Bajor, Judit AU - Sarlós, Patrícia AU - Mikó, Alexandra AU - Márta, Katalin AU - Pécsi, Dániel AU - Párniczky, Andrea AU - Hegyi, Péter TI - In-Hospital Patient Education Markedly Reduces Alcohol Consumption after Alcohol-Induced Acute Pancreatitis. JF - NUTRIENTS J2 - NUTRIENTS VL - 14 PY - 2022 IS - 10 PG - 9 SN - 2072-6643 DO - 10.3390/nu14102131 UR - https://m2.mtmt.hu/api/publication/32849790 ID - 32849790 N1 - * Megosztott szerzőség AB - Although excessive alcohol consumption is by far the most frequent cause of recurrent acute pancreatitis (AP) cases, specific therapy is still not well established to prevent recurrence. Generally, psychological therapy (e.g., brief intervention (BI)) is the cornerstone of cessation programs; however, it is not yet widely used in everyday practice. We conducted a post-hoc analysis of a prospectively collected database. Patients suffering from alcohol-induced AP between 2016 and 2021 received 30 min BI by a physician. Patient-reported alcohol consumption, serum gamma-glutamyl-transferase (GGT) level, and mean corpuscular volume (MCV) of red blood cells were collected on admission and at the 1-month follow-up visit to monitor patients' drinking habits. Ninety-nine patients with alcohol-induced AP were enrolled in the study (mean age: 50 ± 11, 89% male). A significant decrease was detected both in mean GGT value (294 ± 251 U/L vs. 103 ± 113 U/L, p < 0.001) and in MCV level (93.7 ± 5.3 U/L vs. 92.1 ± 5.1 U/L, p < 0.001) in patients with elevated on-admission GGT levels. Notably, 79% of the patients (78/99) reported alcohol abstinence at the 1-month control visit. Brief intervention is an effective tool to reduce alcohol consumption and to prevent recurrent AP. Longitudinal randomized clinical studies are needed to identify the adequate structure and frequency of BIs in alcohol-induced AP. LA - English DB - MTMT ER - TY - JOUR AU - Bunduc, Stefania AU - Gede, Noémi AU - Váncsa, Szilárd AU - Lillik, Veronika AU - Kiss, Szabolcs AU - Juhász, Márk Félix AU - Erőss, Bálint Mihály AU - Szakács, Zsolt AU - Gheorghe, Cristian AU - Mikó, Alexandra AU - Hegyi, Péter TI - Exosomes as prognostic biomarkers in pancreatic ductal adenocarcinoma—a systematic review and meta-analysis JF - TRANSLATIONAL RESEARCH J2 - TRANSL RES VL - 244 PY - 2022 SP - 126 EP - 136 PG - 11 SN - 1931-5244 DO - 10.1016/j.trsl.2022.01.001 UR - https://m2.mtmt.hu/api/publication/32614446 ID - 32614446 N1 - * Megosztott szerzőség AB - Extensive research is focused on the role of liquid biopsy in pancreatic cancer since reliable diagnostic and follow-up biomarkers represent an unmet need for this highly lethal malignancy. We performed a systematic review and meta-analysis on the prognostic value of exosomal biomarkers in pancreatic ductal adenocarcinoma (PDAC). MEDLINE, Embase, Scopus, Web of Science, and CENTRAL were systematically searched on the 18th of January, 2021 for studies reporting on the differences in overall (OS) and progression-free survival (PFS) in PDAC patients with positive versus negative exosomal biomarkers isolated from blood. The random-effects model estimated pooled multivariate-adjusted (AHR) and univariate hazard ratios (UHRs) with 95% confidence intervals (CIs). Eleven studies comprising 634 patients were eligible for meta-analysis. Detection of positive exosomal biomarkers indicated increased risk of mortality (UHR=2.81, CI:1.31-6,00, I2=88.7%, p<0.001), and progression (UHR=3.33, CI: 2.33-4.77, I2=0, p=0.879) across various disease stages. Positive exosomal biomarkers identified preoperatively revealed a higher risk of mortality in resectable stages (UHR=5.55, CI: 3.24-9.49, I2=0, p=0.898). The risk of mortality in unresectable stages was not significantly increased with positive exosomal biomarkers (UHR=2.51, CI: 0.55-11.43, I2=90.3%, p<0.001). Detectable exosomal micro ribonucleic acids were associated with a decreased OS (UHR=4.08, CI: 2.16-7.69, I2=46.9%, p=0.152) across various stages. Our results reflect the potential of exosomal biomarkers for prognosis evaluation in PDAC. The associated heterogeneity reflects the variability of study methods and need for their uniformization before transition to clinical use. LA - English DB - MTMT ER - TY - JOUR AU - Bunduc, Stefania AU - Gede, Noémi AU - Váncsa, Szilárd AU - Lillik, Veronika AU - Kiss, Szabolcs AU - Dembrovszky, Fanni AU - Erőss, Bálint Mihály AU - Szakács, Zsolt AU - Gheorghe, Cristian AU - Mikó, Alexandra AU - Hegyi, Péter TI - Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta–analysis JF - CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY J2 - CRIT REV ONCOL HEMAT VL - 169 PY - 2022 PG - 10 SN - 1040-8428 DO - 10.1016/j.critrevonc.2021.103548 UR - https://m2.mtmt.hu/api/publication/32514829 ID - 32514829 N1 - * Megosztott szerzőség AB - This systematic review and meta-analysis evaluated the prognostic role of cell-free DNA (cfDNA) in pancreatic ductal adenocarcinoma (PDAC). Eligible studies reported differences in overall (OS) and progression-free survival (PFS) by cfDNA status. The random effect model yielded the pooled hazard ratios (HRs) and 95 % confidence intervals (CI). Detection of circulant-tumor DNA (ctDNA), KRAS mutations and other cfDNA alterations constitute detectable cfDNA biomarkers. Altogether, 38 studies (3,318 patients) were eligible. Progression-free and overall survival were decreased with detectable ctDNA (HR = 1.92, 95 %CI:(1.29,2.86);HR = 2.25, 95 %CI:(1.73,2.92)) and KRAS mutations (HR = 1.88, CI:1.22,2.92,);HR = 1.52, 95 %CI:(1.22, 1.90)) respectively, across various stages. In unresectable cases, ctDNA (HR = 2.50, 95 %CI:(1.94,3.23)), but not KRAS mutations (HR = 1.16, 95 %CI:(0.46,2.94)) signaled risk for progression. Detectable cfDNA biomarkers correlated with worse prognosis in resectable cases and if detected during treatment. In conclusion, cfDNA biomarkers indicate accelerated progression and decreased survival in PDAC. Significance of KRAS mutations detection in unresectable cases is to be determined. LA - English DB - MTMT ER - TY - JOUR AU - Kéringer, Patrik AU - Füredi, Nóra AU - Gaszner, Balázs AU - Mikó, Alexandra AU - Pákai, Eszter AU - Fekete, Kata AU - Pótóné Oláh, Emőke AU - Kelava, Leonardo AU - Romanovsky, Andrej A AU - Rumbus, Zoltán AU - Garami, András TI - The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway JF - AMERICAN JOURNAL OF PHYSIOLOGY: ENDOCRINOLOGY AND METABOLISM J2 - AM J PHYSIOL ENDOC M VL - 322 PY - 2022 IS - 1 SP - E10 EP - E23 PG - 14 SN - 0193-1849 DO - 10.1152/ajpendo.00223.2021 UR - https://m2.mtmt.hu/api/publication/32501308 ID - 32501308 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office [FK 138722]; Medical School, University of Pecs [KA-2019-27]; New National Excellence Program of the Hungarian Ministry for Innovation and Technology [UNKP-20-4-II-PTE-547, UNKP-21-3-IIPTE-1317]; Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary [20765-3/2018/FEKUTSTRAT]; European Union; European Social Fund [EFOP-3.6.1-16-2016-00004]; National Research, Development and Innovation Fund of Hungary [2020-4.1.1-TKP2020, TKP2020-IKA-08, NAP 2017-1.2.1-NKP-2017-00002, GINOP-2.3.2-15-2016-00050, MTA-TKI14016, EFOP-3.6.3-VEKOP-16-2017-00009, EFOP3.6.2-16-2017-00008] Funding text: This work was supported by the National Research, Development and Innovation Office Grant FK 138722 (to A.G.), the Medical School, University of Pecs Grant KA-2019-27 (to A.G.), the New National Excellence Program of the Hungarian Ministry for Innovation and Technology Grants UNKP-20-4-II-PTE-547 (to N.F.) and UNKP-21-3-IIPTE-1317 (to Z.R.), the Higher Education Institutional Excellence Program of the Ministry of Human Capacities in Hungary Grant 20765-3/2018/FEKUTSTRAT (to A.G.), and the European Union, cofinanced by the European Social Fund EFOP-3.6.1-16-2016-00004 (to B.G. and A.G.). B.G. was funded by the National Research, Development and Innovation Fund of Hungary, financed under the 2020-4.1.1-TKP2020 funding scheme (Project No: TKP2020-IKA-08); NAP 2017-1.2.1-NKP-2017-00002; GINOP-2.3.2-15-2016-00050; MTA-TKI14016; EFOP-3.6.3-VEKOP-16-2017-00009; and EFOP3.6.2-16-2017-00008. LA - English DB - MTMT ER - TY - CHAP AU - Lillik, Veronika AU - Stefania, Bunduc AU - Váncsa, Szilárd AU - Mikó, Alexandra ED - Kajos, Luca Fanni ED - Bali, Cintia ED - Preisz, Zsolt ED - Polgár, Petra Ibolya ED - Glázer-Kniesz, Adrienn ED - Tislér, Ádám ED - Szabó, Rebeka TI - Meta analysis: Prognostic role of cell-free DNA in pancreatic adenocarcinoma T2 - 10th Jubilee Interdisciplinary Doctoral Conference : Book of Abstracts = 10. Jubileumi Interdiszciplináris Doktorandusz Konferencia : Absztraktkötet PB - Pécsi Tudományegyetem Doktorandusz Önkormányzat CY - Pécs SN - 9789634298205 PY - 2021 SP - 28 EP - 28 PG - 1 UR - https://m2.mtmt.hu/api/publication/32639846 ID - 32639846 LA - English DB - MTMT ER -